Literature DB >> 25201198

p53-independent effects of Mdm2.

Stephen Bohlman1, James J Manfredi.   

Abstract

Mdm2 is best known as the primary negative regulator of p53, but a growing body of evidence suggests that Mdm2 also has a number of functions independent of its role in regulating p53. Although these functions are not yet well-characterized, they have been implicated in regulating of a number of cellular processes, including cell-cycle control, apoptosis, differentiation, genome stability, and transcription, among others. It appears that Mdm2 exerts these functions through a surprisingly wide variety of mechanisms. For example, it has been shown that Mdm2 can ubiquitinate alternative targets, can stimulate the activity of transcription factors, and can directly bind to mRNA to regulate its stability. Dysregulation of p53-independent functions could be responsible for the oncogenic properties of Mdm2 seen even in the absence of p53, and may explain why approximately 10 % of human tumors overexpress Mdm2 instead of inactivating p53 through other mechanisms. As the p53-independent functions of Mdm2 present novel targets for potential therapeutic interventions, fully characterizing these cellular and pathogenic roles of Mdm2 will be important in the study of tumor biology and the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201198      PMCID: PMC5507576          DOI: 10.1007/978-94-017-9211-0_13

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  72 in total

1.  Mdm2 inhibition of p53 induces E2F1 transactivation via p21.

Authors:  Mark Wunderlich; Steven J Berberich
Journal:  Oncogene       Date:  2002-06-27       Impact factor: 9.867

Review 2.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

Review 3.  Divorcing ARF and p53: an unsettled case.

Authors:  Charles J Sherr
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

4.  Regulation of transcriptional activation of mdm2 gene by p53 in response to UV radiation.

Authors:  L J Saucedo; B P Carstens; S E Seavey; L D Albee; M E Perry
Journal:  Cell Growth Differ       Date:  1998-02

5.  Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis.

Authors:  Yeping Wu; Yingying Fu; Lin Zheng; Guanyu Lin; Jian Ma; Jianshu Lou; Hong Zhu; Qiaojun He; Bo Yang
Journal:  Cancer Lett       Date:  2013-08-31       Impact factor: 8.679

6.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

7.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

8.  Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26.

Authors:  Yaara Ofir-Rosenfeld; Kristy Boggs; Dan Michael; Michael B Kastan; Moshe Oren
Journal:  Mol Cell       Date:  2008-10-24       Impact factor: 17.970

9.  MDM2 gene amplification in metastatic osteosarcoma.

Authors:  M Ladanyi; C Cha; R Lewis; S C Jhanwar; A G Huvos; J H Healey
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

10.  Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein.

Authors:  K Martin; D Trouche; C Hagemeier; T S Sørensen; N B La Thangue; T Kouzarides
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

View more
  37 in total

1.  SCFFBXO22 targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis.

Authors:  Jin Bai; Kenneth Wu; Meng-Han Cao; Yingying Yang; Yu Pan; Hui Liu; Yizhou He; Yoko Itahana; Lan Huang; Jun-Nian Zheng; Zhen-Qiang Pan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-28       Impact factor: 11.205

2.  Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Bhavitavya Nijampatnam; Sadanandan E Velu; Ke-He Ruan; Ming Hu; Jianwei Zhou; Ruiwen Zhang
Journal:  Cancer Res       Date:  2018-09-14       Impact factor: 12.701

3.  MDM2 controls gene expression independently of p53 in both normal and cancer cells.

Authors:  Giuseppe Arena; Romain Riscal; Laetitia K Linares; Laurent Le Cam
Journal:  Cell Death Differ       Date:  2018-07-23       Impact factor: 15.828

4.  The Expression of P53, MDM2, c-myc, and P14ARF Genes in Newly Diagnosed Acute Lymphoblastic Leukemia Patients.

Authors:  Mehdi Allahbakhshian Farsani; Mohammad Rafiee; Hamideh Aghaee Nezhad; Sina Salari; Arshia Gharehbaghian; Mohammad Hossein Mohammadi
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-16       Impact factor: 0.900

5.  MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.

Authors:  Wei Wang; Jian-Wen Cheng; Jiang-Jiang Qin; Bo Hu; Xin Li; Bhavitavya Nijampatnam; Sadanandan E Velu; Jia Fan; Xin-Rong Yang; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2019-06-07       Impact factor: 8.679

Review 6.  Reviving the guardian of the genome: Small molecule activators of p53.

Authors:  Daniel Nguyen; Wenjuan Liao; Shelya X Zeng; Hua Lu
Journal:  Pharmacol Ther       Date:  2017-03-27       Impact factor: 12.310

7.  MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53.

Authors:  Magdalena Wienken; Antje Dickmanns; Alice Nemajerova; Daniela Kramer; Zeynab Najafova; Miriam Weiss; Oleksandra Karpiuk; Moustapha Kassem; Yanping Zhang; Guillermina Lozano; Steven A Johnsen; Ute M Moll; Xin Zhang; Matthias Dobbelstein
Journal:  Mol Cell       Date:  2015-12-31       Impact factor: 17.970

8.  Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms.

Authors:  Wei Wang; Jiang-Jiang Qin; Xin Li; Guanyu Tao; Qiang Wang; Xuming Wu; Jianwei Zhou; Xiaolin Zi; Ruiwen Zhang
Journal:  Carcinogenesis       Date:  2018-07-30       Impact factor: 4.944

Review 9.  Targeting MDM2 for novel molecular therapy: Beyond oncology.

Authors:  Wei Wang; Jiang-Jiang Qin; Mehrdad Rajaei; Xin Li; Xiaoyi Yu; Courtney Hunt; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2019-10-06       Impact factor: 12.944

10.  MDM2 Derived from Dedifferentiated Liposarcoma Extracellular Vesicles Induces MMP2 Production from Preadipocytes.

Authors:  Lucia Casadei; Federica Calore; Danielle A Braggio; Abeba Zewdu; Ameya A Deshmukh; Paolo Fadda; Gonzalo Lopez; Martin Wabitsch; Chi Song; Jennifer L Leight; Valerie P Grignol; Dina Lev; Carlo M Croce; Raphael E Pollock
Journal:  Cancer Res       Date:  2019-08-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.